운동신경세포병의 임상 척도

키워드

참고문헌 (43)

1. Brown RH, "Amyotrophic Lateral Sclerosis", N Engl J Med, 377, pp.162~172 (2017)
2. van Es MA, "Amyotrophic lateral sclerosis", Lancet, 390, pp.2084~2098 (2017)
3. 최영숙, "아밀로이드베타단백(Aβ1-42)투여 후 마우스 소교세포의 활성산소종 생성과 보체조절유전자의 발현 및 탐식", 대한신경과학회지, 23(1), pp.88~95 (2005), 대한신경과학회
4. McDermott CJ, "Clinical trials in amyotrophic lateral sclerosis", Curr Opin Neurol, 32, pp.758~763 (2019)
5. van den Berg LH, "Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials", Neurology, 92, pp.e1610~e1623 (2019)
6. Mitsumoto H, "Amyotrophic Lateral Sclerosis", pp.329~359 (1998), F. A. Davis Company
7. Miller RG, "Consensus guidelines for the design and implementation of clinical trials in ALS. World Federation of Neurology committee on Research", J Neurol Sci, 169, pp.2~12 (1999)
8. Cedarbaum JM, "The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III)", J Neurol Sci, 169, pp.13~21 (1999)
9. 김현영, "한글판 Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised : 신뢰도와 타당도에 관한 예비연구", 대한신경과학회지, 25(2), pp.149~154 (2007), 대한신경과학회
10. Kimura F, "Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS", Neurology, 66, pp.265~267 (2006)
11. Castrillo-Viguera C, "Clinical significance in the change of decline in ALSFRS-R", Amyotroph Lateral Scler, 11, pp.178~180 (2010)
12. Appel V, "A rating scale for amyotrophic lateral sclerosis: description and preliminary experience", Ann Neurol, 22, pp.328~333 (1987)
13. Moore SR, "A self-report measure of affective lability", J Neurol Neurosurg Psychiatry, 63, pp.89~93 (1997)
14. Smith R, "Enhanced bulbar function in amyotrophic lateral sclerosis: the Nuedexta treatment trial", Neurotherapeutics, 14, pp.762~772 (2017)
15. Brooks BR, "Treatment of pseudobulbar affect in ALS with dextromethorphan", quinidine: a randomized trial, 2004, pp.63, 1364~1370
16. 조희진, "근위축측삭경화증에서 Nuedexta (Dextromethorphan and Quinidine)의 연수기능 개선에 대한 증례", 대한신경과학회지, 37(2), pp.171~173 (2019), 대한신경과학회
17. Gonnella JS, "Staging of disease. A case-mix measurement", JAMA, 251, pp.637~644 (1984)
18. Roche JC, "A proposed staging system for amyotrophic lateral sclerosis", Brain, 135, pp.847~852 (2012)
19. Chiò A, "Development and evaluation of a clinical staging system for amyotrophic lateral sclerosis", J Neurol Neurosurg Psychiatry, 86, pp.38~44 (2015)
20. Fang T, "Comparison of the King’s and MiToS staging systems for ALS", Amyotroph Lateral Scler Frontotemporal Degener, 18, pp.227~232 (2017)
21. Ferraro D, "Amyotrophic lateral sclerosis: a comparison of two staging systems in a population-based study", Eur J Neurol, 23, pp.1426~1432 (2016)
22. Brooks BR, "El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases", Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial “Clinical limits of amyotrophic lateral sclerosis”workshop contributors, 1994, pp.124(Suppl), 96~107
23. Strong MJ, "Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): revised diagnostic criteria", Amyotroph Lateral Scler Frontotemporal Degener, 18, pp.153~174 (2017)
24. Oh SI, "Spectrum of cognitive impairment in Korean ALS patients without known genetic mutations", PLoS One, 9, pp.e87163~ (2014)
25. Oh J, "Socioeconomic costs of amyotrophic lateral sclerosis according to staging system", Amyotroph Lateral Scler Frontotemporal Degener, 16, pp.202~208 (2015)
26. Chen X, "Clinical staging of amyotrophic lateral sclerosis in chinese patients", Front Neurol, 9, pp.442~ (2018)
27. Rhodes LE, "Clinical features of spinal and bulbar muscular atrophy", Brain, 132, pp.3242~3251 (2009)
28. Katsuno M, "Efficacy and safety of leuprorelin in patients with spinal and bulbar muscular atrophy (JASMITT study): a multicentre, randomised, double-blind, placebo-controlled trial", Lancet Neurol, 9, pp.875~884 (2010)
29. Hashizume A, "A functional scale for spinal and bulbar muscular atrophy: cross-sectional and longitudinal study", Neuromuscul Disord, 25, pp.554~562 (2015)
30. Querin G, "Validation of the Italian version of the SBMA Functional Rating Scale as outcome measure", Neurol Sci, 37, pp.1815~1821 (2016)
31. 오성일, "Reliability and Validity of the Korean Version of the Spinal and Bulbar Muscular Atrophy Functional Rating Scale", Journal of Clinical Neurology, 16(4), pp.586~591 (2020), 대한신경과학회[DOI]
32. Lunn MR, "Spinal muscular atrophy", Lancet, 371, pp.2120~2133 (2008)
33. Finkel RS, "Nusinersen versus sham control in infantile-onset spinal muscular atrophy", N Engl J Med, 377, pp.1723~1732 (2017)
34. Dunaway Young S, "Six-minute walk test is reliable and valid in spinal muscular atrophy", Muscle Nerve, 54, pp.836~842 (2016)
35. Main M, "The Hammersmith functional motor scale for children with spinal muscular atrophy: a scale to test ability and monitor progress in children with limited ambulation", Eur J Paediatr Neurol, 7, pp.155~159 (2003)
36. Krosschell KJ, "A modified Hammersmith functional motor scale for use in multi-center research on spinal muscular atrophy", Neuromuscul Disord, 16, pp.417~426 (2006)
37. Montes J, "Ambulatory function in spinal muscular atrophy: age-related patterns of progression", PLoS One, 13, pp.e0199657~ (2018)
38. Wadman RI, "Muscle strength and motor function throughout life in a cross-sectional cohort of 180 patients with spinal muscular atrophy types 1c-4", Eur J Neurol, 25, pp.512~518 (2018)
39. Mazzone E, "Assessing upper limb function in nonambulant SMA patients: development of a new module", Neuromuscul Disord, 21, pp.406~412 (2011)
40. Mazzone ES, "Revised upper limb module for spinal muscular atrophy: development of a new module", Muscle Nerve, 55, pp.869~874 (2017)
41. Pera MC, "Revised upper limb module for spinal muscular atrophy: 12 month changes", Muscle Nerve, 59, pp.426~430 (2019)
42. Cano SJ, "Rasch analysis of clinical outcome measures in spinal muscular atrophy", Muscle Nerve, 49, pp.422~430 (2014)
43. Chabanon A, "Prospective and longitudinal natural history study of patients with type 2 and 3 spinal muscular atrophy: Baseline data NatHis-SMA study", PLoS One, 13, pp.e0201004~ (2018)

관련 논문AI추천